• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

apremilast (Otezla) - Articles and news items

apremilast

NICE says ‘no’ to apremilast for psoriatic arthritis

Industry news / 3 September 2015 / Victoria White

NICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis…

Celgene

Celgene’s Otezla® (Apremilast) receives European Marketing Authorisation

Industry news / 19 January 2015 / Celgene

An oral therapy for moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis, with no drug-specific pre-screening or laboratory monitoring requirements…

Celgene Logo

Celgene receives positive CHMP opinion for OTEZLA® (apremilast)

Industry news / 24 November 2014 / Celgene International Sàrl

Celgene receives positive CHMP opinion for OTEZLA® (apremilast), the first oral PDE4 inhibitor for the treatment of patients with psoriasis and psoriatic arthritis…

Celgene Logo

Oral apremilast significantly improved nail and scalp psoriasis and health-related quality of life measures in phase III esteem 1 study

Industry news / 3 October 2013 / Celgene

Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +